Scott Blumberg Sells 1,387 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,387 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $24,966.00. Following the transaction, the chief financial officer owned 147,683 shares in the company, valued at approximately $2,658,294. This represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Price Performance

NASDAQ CBLL opened at $18.70 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The firm’s 50 day moving average price is $19.08 and its 200-day moving average price is $19.29. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The company has a market cap of $709.48 million, a PE ratio of -11.47 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. Sell-side analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of CBLL. Bank of New York Mellon Corp grew its holdings in CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after purchasing an additional 1,162,200 shares during the last quarter. KCM Capital Inc purchased a new position in CeriBell in the fourth quarter worth $21,930,000. Royce & Associates LP purchased a new position in CeriBell in the fourth quarter worth $11,695,000. Adage Capital Partners GP L.L.C. purchased a new position in CeriBell in the fourth quarter worth $10,965,000. Finally, CenterBook Partners LP grew its holdings in CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after purchasing an additional 389,584 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on CBLL shares. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Canaccord Genuity Group dropped their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Finally, Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.